VolitionRx
VNRX
17 hedge funds and large institutions have $18.8M invested in VolitionRx in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
0% more funds holding
Funds holding: 17 → 17 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.51% less ownership
Funds ownership: 18.39% → 17.89% (-0.51%)
89% less capital inflows, than outflows
Capital inflows: $69.6K | Capital outflows: $624K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$38.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$15.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.2K |
| 4 |
Bank of New York Mellon
New York
|
+$2.74K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$2.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lagoda Investment Management
New York
|
-$599K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$20K |
| 3 |
Morgan Stanley
New York
|
-$4.42K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$1.33K |
VNRX Hedge Fund Activity: Q1 2017 in Review
17 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in VolitionRx (VNRX) for Q1 2017, worth a combined $18.8M — down 14% from $21.9M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VNRX positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Northern Trust, adding an estimated $38.7K. The largest seller was Lagoda Investment Management, cutting an estimated $599K.
- 17 institutional investors held VolitionRx (VNRX) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $18.8M of VolitionRx stock for Q1 2017, down 14% quarter-over-quarter.
- 2 funds opened new VolitionRx positions in Q1 2017 and 1 closed out, a net change of +1 holder.
- The largest VolitionRx buyer in Q1 2017 was Northern Trust, an estimated $38.7K added.
- The largest VolitionRx seller in Q1 2017 was Lagoda Investment Management, an estimated $599K sold.
Based on aggregated 13F filings for Q1 2017.